[Does aluminum affect the effectiveness of human recombinant erythropoietin in the treatment of anemia in dialyzed patients?].
In five female patients with chronic renal failure who had regular dialyzation treatment it was revealed that hyperaluminaemia reduces the effect of erythropoietin. In view of the high cost of this drug it is reasonable to maintain the aluminium value at the lowest levels.